Overview
Maturity-onset diabetes of the young (MODY) refers to a group of monogenic forms of diabetes characterized by early onset, autosomal dominant inheritance, and specific genetic mutations affecting beta-cell function. MODY subtypes often respond uniquely to therapeutic interventions, particularly sulfonylureas.Diagnosis
Genetic testing identifying mutations in MODY-related genes (ABCC8, HNF1A) 12.
Detailed phenotyping including oral glucose tolerance tests and insulin response analysis 1.
Elevated fasting glucose levels, typically without ketoacidosis 1.
Increased skeletal muscle capillary basement membrane width in younger patients, though not age-dependent thickening 3.Management
First-line treatment: Sulfonylurea therapy, particularly effective in ABCC8 and HNF1A-MODY 12.
Dose adjustment: Low-dose sulfonylurea often sufficient for stable glycaemic control 1.
Monitoring: Regular HbA1c assessments to evaluate long-term glucose control 2.
Avoidance: Minimize or discontinue insulin therapy to reduce hypoglycemic risk 1.Special Populations
Pregnancy: Specific management strategies not detailed in provided abstracts; individualized care recommended [Expert opinion].
Complications: High prevalence of microvascular complications noted, particularly in certain ethnic groups like Indians; macrovascular complications appear less frequent 4.Key Recommendations
Initiate sulfonylurea therapy as first-line treatment for ABCC8 and HNF1A-MODY to achieve stable glycaemic control and reduce hypoglycemic events (Evidence: Strong 1).
Regular follow-up and monitoring of HbA1c levels are essential to manage glycaemic control effectively in MODY patients (Evidence: Moderate 2).
Consider genetic testing early in the diagnostic process to identify specific MODY subtypes and tailor therapy accordingly (Evidence: Moderate 12).References
1 Reilly F, Sanchez-Lechuga B, Clinton S, Crowe G, Burke M, Ng N et al.. Phenotype, genotype and glycaemic variability in people with activating mutations in the ABCC8 gene: response to appropriate therapy. Diabetic medicine : a journal of the British Diabetic Association 2020. link
2 Bacon S, Kyithar MP, Rizvi SR, Donnelly E, McCarthy A, Burke M et al.. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort. Diabetic medicine : a journal of the British Diabetic Association 2016. link
3 Mauer M, Steffes M, Johnson E, Rich S, Hoogwerf B, Chavers B et al.. Skeletal muscle basement membrane in maturity-onset diabetes in the young. Diabetes 1985. link
4 Mohan V, Ramachandran A, Snehalatha C, Mohan R, Bharani G, Viswanathan M. High prevalence of maturity-onset diabetes of the young (MODY) among Indians. Diabetes care 1985. link